New US Indication May Help Finally Get Keryx' Auryxia Off The Ground
Company plans to use the same sales force and broad insurance coverage for oral iron product in new use for CKD patients with iron deficiency anemia not on dialysis, as for the first approved use in dialysis patients, so it will "hit the ground running."
You may also be interested in...
Planned all-stock transaction would bring together Akebia’s R&D organization and Keryx’s commercial apparatus for Auryxia. That drug and Akebia’s Phase III vadadustat would create a complementary franchise, CEO Butler asserts.
Keryx plans to expand Aurexia’s label to treat iron deficiency in pre-dialysis patients while searching for additional nephrology assets during 2017.
Keryx Biopharmaceuticals Inc. had a rough first year of sales for its oral, iron-based phosphate binder Auryxia (ferric citrate), but the company and it investors have high hopes that new Phase III data will support approval for a second indication that could double the drug's market.